Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Acute upper limb ischemia in a patient with newly diagnosed paroxysmal atrial fibrillation

  • Kim, Dong Shin (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Kim, Seunghwan (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Min, Hyang Ki (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Song, Chiwoo (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Kim, Young Bin (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Kim, Sae Jong (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Park, Ji Young (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Ryu, Sung Kee (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine) ;
  • Choi, Jae Woong (Department of Cardiology, Seoul Eulji Hospital, Eulji University College of Medicine)
  • 투고 : 2016.06.28
  • 심사 : 2016.08.16
  • 발행 : 2017.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Acute limb ischemia (ALI) due to an embolism is associated with high mortality rate and poor prognosis, and early diagnosis with prompt revascularization is required to reduce the risk of limb amputation or even death. The etiologies of ALI are diverse, and it includes an embolism from the heart and thrombotic occlusion of the atherosclerotic native vessels, stents, or grafts. An uncommon cause of ALI is acute arterial thromboembolism, and atrial fibrillation (AF) is the single most important risk factors for systemic thromboembolism. It is important to correctly identify the source of ALI for secondary prevention, as it depends on the underlying cause. Percutaneous transluminal angioplasty (PTA) has been proven to be a safe and effective treatment for focal atherosclerotic and thrombotic occlusive diseases of the aorta and its major extremity branches. Herein, we report on a 77-year-old female patient with acute upper limb ischemia, treated by PTA using a catheter-guided thrombectomy. He was newly diagnosed with paroxysmal AF (PAF) while evaluation the cause of his acute arterial thromboembolism. We recommend that cardiologists always consider PAF as a possible diagnosis even in patients without any history of AF under ALI because it is possible to develop thromboembolism in clinical practice.

키워드

참고문헌

  1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67. https://doi.org/10.1016/j.jvs.2006.12.037
  2. Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med 2012;366:2198-206. https://doi.org/10.1056/NEJMcp1006054
  3. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354. https://doi.org/10.1161/circ.114.4.257
  4. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008;29:1181-9. https://doi.org/10.1093/eurheartj/ehn139
  5. Andersen LV, Lip GY, Lindholt JS, Frost L. Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. J Thromb Haemost 2013;11:836-44. https://doi.org/10.1111/jth.12181
  6. Andersen LV, Mortensen LS, Lindholt JS, Faergeman O, Henneberg EW, Frost L. Upper-limb thrombo-embolectomy: national cohort study in Denmark. Eur J Vasc Endovasc Surg 2010;40:628-34. https://doi.org/10.1016/j.ejvs.2010.06.009
  7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. https://doi.org/10.1056/NEJMoa0905561
  8. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17. https://doi.org/10.1056/NEJMoa1007432
  9. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding:a systematic review and meta-analysis. Eur Heart J 2016;37:1591-602. https://doi.org/10.1093/eurheartj/ehw007
  10. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000;35:183-7. https://doi.org/10.1016/S0735-1097(99)00489-1
  11. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61. https://doi.org/10.1016/j.jacc.2007.07.076
  12. Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation:a meta-analysis. Heart 2008;94:1607-13. https://doi.org/10.1136/hrt.2007.135657
  13. Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J 2015;170:669-74. https://doi.org/10.1016/j.ahj.2015.06.020